参附注射液治疗急性心肌梗塞患者疗效观察

摘要

Objective: To study effects of shenfu injection on levels of superoxide dismutase (SOD), malonyl diadehyde (MDA), C—reactive protein (CRP), N terminal-pro brain natriuretic peptide (NT—proBNP) and cardiac function in patients with acute myocardial infarction (AMI) and investigate whether shenfu injection can protect myocardium of AMI patients. Methods: A total of 56 AMI patients were randomly divided into routine treatment group (n=28, received routine treatment without any Chinese patent medicine) and shenfu injection treatment group (shenfu group, n = 28,received shenfu injection 20～30ml on the basis of routine treatment for 14d, intravenous drop infusion once daily). Blood levels of SOD, MDA, CRP and NT—proBNP of each group were measured before and after therapy. Cardiac output (CO) , cardiac index (CD and left ventricular ejection fraction (LVEF) were measured at the same time. Results : After treatment, all indexes of the two groups significantly improved (P＜0. 05 all); compared with routine treatment group, levels of MDA [ (56. 4 ± 9. 5) nmol/ml vs. (45. 6±9. 8) nmol/ml], CRP [ (9. 5±4. 3) mg/L vs. (7. 3±3. 7) mg/L] and NT—proBNP [(987±42. 3) pg/ml vs. (784±37. 6) pg/ml] significantly decreased (P＜0. 05 all), levels of SOD [ (46. 7±9. 7) U/L vs. (58.1±10.7) U/L], CO [ (4.8±1. 1) L/min vs. (5.5 ± 1.2) L/min], CI [ (2. 8±0. 8) L/m2 · min vs. (3. 6±0. 7) L/m2 · min] and LVEF [ (55±2. 1) ％ vs. (57±2. 0) ％] significantly increased in shenfu injection treatment group after therapy, P＜0. 05 all. Conclusion: Shenfu injection can increase the ability of cleaning oxygen free radical, decrease inflammatory reaction and improve cardiac function, therefore it possesses effect of protect myocardium in AMI patients.%目的:观察参附注射液对急性心肌梗塞(AMI)患者超氧化物歧化酶(SOD)、丙二醛(MDA)、C反应蛋白(CRP)、N末端脑钠肽前体(NT-proBNP)水平及心功能的影响,及其对AMI患者心肌是否具有保护作用.方法:AMI患者共56例,随机分为常规治疗组28例,给予常规治疗,不加用任何中成药物;参附组28例,在常规治疗基础上加用参附注射液20ml～30ml,每日一次静脉滴注,疗程为14d.治疗前后采血测定各组SOD、MDA、CRP、NT-proBNP水平;同时测定心功能心输出量(CO)、心脏指数(CI)、左室射血分数(LVEF).结果:两组治疗后,各指标均有明显改善(P均<0.05);与常规治疗组治疗后比较,参附组MDA[(56.4±9.5) nmol/ml∶(45.6±9.8) nmol/ml]、CRP[(9.5±4.3) mg/L∶(7.3±3.7) mg/L]、NT-proBNP [(987±42.3) pg/ml∶(784±37.6) pg/ml]水平明显降低(P均<0.05),而SOD含量[(46.7±9.7) U/L∶(58.1±10.7) U/L],CO[(4.8±1.1) L/min∶(5.5±1.2) L/min]、CI[(2.8±0.8) L/m2·min∶(3.6±0.7) L/m2·min]、LVEF[(55±2.1) %∶(57±2.0) %]明显升高(P均<0.05).结论:参附注射液能增强急性心肌梗塞患者清除氧自由基的能力,降低炎症反应,改善心功能,从而对急性心肌梗塞患者心肌有保护作用.